We're working on profiling this company soon. Let us know you're interested by sending us a request here »
We're working hard to bring you this company's profile. Register here to get an alert as soon we're done.
In the meantime, if you are interested in participating in placements on this stock click "Follow" on the toolbar above.
Albanese govt announces the Future Made in Australia Act Why supporting Australian Made is a win-wi...
Read ArticleThe ASX200 closed the day up more than a per cent (1.08%). All sectors bar one finished in the gr...
Read ArticleRecce Pharmaceuticals (ASX:RCE), developing a body of anti-infective drugs for Australian and intern...
Read ArticleThe ASX200 has shed nearly double what futures predicted, trading down 2.05% All 11 sectors are i...
Read ArticleRecce Pharmaceuticals (ASX:RCE) is trading up more than 6 per cent after producing a 5000-dose batch...
Read ArticleResearch reports on ASX-listed companies, to download in full. **** -Amaero International ((3DA)) by...
Read ArticleRecce Pharmaceuticals (ASX:RCE) published a business update highlighting two key developments with t...
Read ArticleThe ASX200 is trading down around 1.19 per cent, taking a slight respite from yesterday’s all-time h...
Read ArticleRecce Pharmaceuticals (ASX:RCE) has successfully obtained its first patent for its flagship anti-inf...
Read ArticleThe ASX200 had a stellar run on Thursday, closing up more than one point ten per cent. All secto...
Read ArticleThe ASX200 has run up 1.16 per cent to be trading in record territory at 7,785 points. All sector...
Read ArticleRecce Pharmaceuticals (ASX: RCE), who has been pioneering a new class of synthetic anti-infectives,...
Read ArticleThe ASX200 has traded down well over a per cent this morning – performing worse than predicted. A...
Read ArticleRecce Pharmaceuticals Limited (ASX: RCE) has completed tests involving a four-person cohort for its...
Read ArticleThere was good news for those with property investments today… the median price of a house in Austra...
Read ArticleRecce Pharmaceuticals (ASX: RCE) (FSE: R9Q) announces the successful dosing of the latest group of h...
Read ArticleThe weekend begins after a day of record breaking on the ASX. The ASX200 closed well over a per cent...
Read ArticleRecce Pharmaceuticals announces the receipt of an AUD$11,178,965 R&D Advance from Endpoints Capi...
Read ArticleResearch reports on ASX-listed companies, to download in full. **** -Actinogen Medical ((ACW)) by Ed...
Read ArticleASX closed flat, as Coles-led Staples sector gained Iron ore stocks under pressure as iron ore futu...
Read ArticleThe ASX200 has been trading fairly flat, having headed down about .2 per cent earlier in the session...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) has followed Wall Street's lead and dropped into the red. In...
Read ArticleRecce Pharmaceuticals (ASX:RCE) highlights ongoing initiatives within its Anti-Infective Research (A...
Read ArticleRecce Pharma says Phase 1/2 study is achieving primary endpoints Cynata also reports also reports g...
Read ArticleRecce Pharmaceuticals’ (ASX:RCE) flagship product is a versatile drug called R327 It can be used...
Read ArticleRecce Pharmaceuticals (ASX:RCE) has signed a Memorandum of Understanding with Indonesian org...
Read ArticleWe’re here for day two of the RIU Resurgence conference in Perth, and it’s certainly busy here with...
Read ArticleRecce Pharmaceuticals (ASX:RCE) develops anti-infectives for a range of issues and post-surgical com...
Read ArticleShortly before Without A Fight crossed the finish line to win the 2023 Melbourne Cup, the Reserve Ba...
Read ArticleThe Reserve Bank of Australia has decided to lift the cash rate again — upping it by 25 basis points...
Read ArticleRecce Pharmaceuticals (ASX:RCE) completes dosing of the first male and female subjects in its UTI/ur...
Read ArticleThe ASX200 lifted nearly 0.2 of a per cent by the end of the day’s session, with materials taking a...
Read ArticleRecce Pharmaceuticals (ASX:RCE) UTI trial using flagship anti-infective R327 has been greenlit to go...
Read ArticleRecce Pharma moves forward to stronger dose in Phase 1/2 trial EMV is bench testing its 2nd Gen ult...
Read ArticleThe ASX200 is down nearly 1.2 percent with most sectors in the red. Energy is the only sector making...
Read ArticleRecce Pharmaceuticals (ASX:RCE) winds up the September quarter with $8 million in cash The compa...
Read ArticleSonia Madigan: Recce Pharmaceuticals (ASX:RCE) has raised $11 million to continue developing its...
Read ArticleRecce Pharmaceuticals (ASX:RCE) is fast-tracking the development of its synthetic class of potent an...
Read ArticleThe ASX200 ended the week up just, despite the week’s losses totalling more than one and half per ce...
Read ArticleWhilst the ASX200 has slipped .6 of a per cent, that performance is considerably better than futures...
Read ArticleRecce Pharmaceuticals (RCE) completes dosing its male and female subjects in its phase I/II UTI clin...
Read ArticleTreatment for infectious diseases continues to pose a significant threat to populations worldwide, w...
Read ArticleResearch reports on ASX-listed companies, to download in full. **** –Actinogen Medical ((ACW)) by Ed...
Read ArticleRecce Pharmaceuticals (ASX: RCE), a company developing a new class of synthetic antibiotics, is rais...
Read ArticleThe ASX200 gradually climbed today to gain close to half a per cent. Financials registered the highe...
Read ArticleThe Recce Pharmaceuticals Ltd (ASX: RCE) share price has returned from a trading halt and crashed d...
Read ArticleRecce Pharmaceuticals (RCE) is raising up to $11 million through a strongly supported placement and...
Read ArticleASX 200 closes about 0.3% lower, down well over 2.2% for the week. Materials and Consumer discreti...
Read ArticleThe ASX200 has traded down about point four of a per cent this morning. Sector performances vari...
Read ArticleThe Australian stock market has dropped more than three-quarters of a per cent in the first hours of...
Read ArticleCannabis biotech Bod surges after good clinical trial results Imricor granted US$1.15m award in the...
Read ArticleRecce Pharmaceuticals (RCE) secures trademark registration for RECCE in Vietnam It was issued by...
Read ArticleRecce Pharmaceuticals (RCE) reports its R327 gel product saw one elderly patient avoid amputation of...
Read ArticleRecce Pharmaceuticals (RCE) receives the green light to advance to the next cohort of its anti-infec...
Read ArticleRecce Pharmaceuticals (RCE) kicks off its phase I/II diabetic foot infection trial The company w...
Read ArticleRecce Pharmaceuticals’ (RCE) phase I/II R327 topical burn wound clinical trial successfully treats b...
Read ArticleThe ASX has seen a slight lift, up almost 0.2 per cent in early afternoon trade. Materials are le...
Read ArticleMesoblast Ltd (ASX: MSB) shares are sliding again on Tuesday. Shares in the ASX biotech company are...
Read ArticleRecce Pharma surges 20pc on anecdotal results Emyria launches a ketamine-assisted therapy (KAT) pro...
Read ArticleStockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) pe...
Read ArticleRecce Pharmaceuticals (RCE) RCE 327 Gel shows promise in treating multiple antibiotic-resistant infe...
Read ArticleRecce Pharmaceuticals (RCE) is granted a new patent in Australia protecting its in-house R327 and R5...
Read ArticleThe ASX200 closed 0.7 per cent down to finish the week. Only energy, IT and utilities sectors end...
Read ArticleThe ASX 200 has been trading down almost a per cent – energy’s the only sector making gains and onl...
Read ArticleRecce Pharmaceuticals’ (RCE) phase I/II trial partner has wrapped up the second-stage dosages of its...
Read ArticleRecce Pharmaceutical’s (RCE) flagship anti-infective UTI treatment R327 was proven to be safe last w...
Read ArticleThe ASX is trading well today up nearly half a per cent with only the materials and communications s...
Read ArticleRecce Pharmaceuticals (RCE) announces “positive” results from its completed phase one study of anti-...
Read ArticleThe Reserve Bank Governor Phillip Lowe would like to continue in the role he’s held since 2016. S...
Read ArticleRecce Pharmaceuticals (RCE) receives $801,604 from Radium Capital as part of Recce’s future research...
Read ArticleRecce Pharmaceuticals (ASX:RCE) has announced that its Phase 1/2 clinical trial evaluating R...
Read ArticleThe ASX 200 has dipped just a little in early trade. Exploration company Dreadnought Resources (D...
Read ArticleRecce Pharmaceuticals is developing an IV-administered treatment for Urinary Tract Infections (UTIs)...
Read ArticleRecce Pharmaceuticals (RCE) gains approval from the Human Research Ethics Committee to expand its ph...
Read ArticleThe ASX is tracking up in midday trade, with mining giants and the big four banks all in positive te...
Read ArticleRecce Pharmaceuticals (RCE) appoints outpatient nurses from leading healthcare provider Ascott Th...
Read ArticleThe ASX opened on a higher note today, with real estate, energy, and banking stocks contributing to...
Read ArticleRecce Pharmaceuticals (RCE) secures sponsorship from the West Australian government to attend BIO Ko...
Read ArticleDeveloping a drug that is safe and effective for public use is no easy feat. It requires years of cl...
Read ArticleRecce Pharmaceuticals (RCE) receives Human Research Ethics Committee (HREC) approval to start a phas...
Read ArticleRecce Pharmaceuticals (RCE) last year confirmed the safety of its R327 antibiotics treatment for hum...
Read ArticleRecce Pharmaceuticals (RCE) receives boost from the Australian Patent Office after announcing its ‘i...
Read ArticleThe ASX is tipped to open slightly higher on Tuesday following the slight rise to ASX futures when t...
Read ArticleRecce Pharmaceuticals (ASX:RCE) has announced that the Australian Patent Office has issued n...
Read ArticleThe ASX 200 will open slightly higher on Tuesday Tesla to expand in China to produce mega batteries...
Read ArticleEnergy stocks have surged in early trade after OPEC’s controversial move to cut oil production by on...
Read ArticleRecce Pharmaceuticals (RCE) pockets a further $973,144 from Radium Capital as part of Recce’s future...
Read ArticleRecce Pharmaceuticals (ASX:RCE) has received further non-dilutive funds from Radium Capital...
Read ArticleRecce Pharmaceuticals (RCE) selects CMAX Clinical Research in South Australia as the independent fac...
Read ArticleHeraMED’s first commercial rollout in the US is progressing well Recce Pharma is set to commence Ph...
Read ArticleRecce Pharmaceuticals (RCE) receives ‘RECCE’ trademark from the Trade Marks Registry Intellectual Pr...
Read ArticleRecce Pharmaceuticals (RCE) pockets a research and development (R&D) refund of $6.21 million...
Read ArticleRecce receives a grant intent from the Australian Patent Office for an antivirus agent targeting meg...
Read ArticleThe share market pared four days of gains following a mixed night on Wall Street as investors took s...
Read ArticleShares in Perth-founded Recce Pharmaceuticals have lifted after the company announced it had receive...
Read ArticleThe share market retreated for the first time in five sessions after Wall Street’s winning start to...
Read ArticleRecce Pharmaceuticals (RCE) receives a notification of intent to grant an Australian patent for synt...
Read ArticleRecce Pharmaceuticals (RCE) receives a notification of intent to grant an Australian patent for synt...
Read ArticleMGC Pharma completes pre-clinical study on CimetrA Recce Pharma close to getting Aussie patent AdAl...
Read ArticleIt can take a long time to bring a new drug to market, but companies that succeed reap mighty reward...
Read ArticleThe long and short of 2022 is that it was a frustrating period for the Australian biotech sector but...
Read ArticleWhat a day it’s been, what a magic day… and other children’s song lyrics that probably won’t make mu...
Read ArticleRecce Pharmaceuticals (RCE) establishes a new anti-infective research unit within the Murdoch Childr...
Read ArticleRecce Pharmaceuticals (RCE) receives Human Research Ethics Committee (HREC) approval to start a phas...
Read ArticleHITIQ signs with UK rugby league Recce receives ethics approval to commence Phase 1/2 trial Healiu...
Read ArticleASX 200 down 0.55% on lower than normal volume Small cap index falls 0.96% and 10 out 11 sectors...
Read ArticleRecce Pharmaceuticals (RCE) has multiple trials in the pipeline following the September quarterRCE r...
Read ArticleIt’s Tuesday afternoon, and after a long, hard day buying and selling bits of paper that say you own...
Read ArticleRecce Pharmaceuticals (RCE) reports that independent studies of its RECCE 327 (R327) product found t...
Read ArticleHighlights: The ASX 200 benchmark index closed up today, gaining 0.41% to end at 6,496.20 points...
Read ArticleRecce Pharmaceuticals (RCE) updates its clinical timeline, with several data read-outs expected over...
Read ArticlePYC Therapeutics and Race Oncology announce new RNA programs Recce Pharma accelerates its clinical...
Read ArticleReece Pharmaceuticals (RCE) will deliver the opening research and development address at the World A...
Read ArticleRecce Pharmaceuticals (ASX:RCE) has announced the appointment of Dr John Prendergast as its...
Read ArticleHighlights The ASX 200 benchmark index closed up today (5 September), gaining 0.34% to end at 6,...
Read ArticleRecce Pharmaceuticals (RCE) appoints Dr John Prendergast as Executive Chairman, effective immediatel...
Read ArticleImaging specialist Clarity opens patient recruitment in Australia and will start Phase 2 trial soon...
Read ArticleRecce Pharmaceuticals (RCE) reports no serious adverse effects from intravenously dosing the sevent...
Read ArticleThe ASX is poised to open lower on Monday Wall Street ends a four-week winning streak last week Oil...
Read ArticleRecce Pharmaceuticals (RCE) progresses clinical trials of its R327 drug candidate during the June q...
Read ArticleEmerging Australian company Recce Pharmaceuticals (ASX:RCE) has appointed an experienced ind...
Read ArticleRecce Pharmaceuticals (RCE) appoints Dr Philip Sutton as Vice President of Translational Sciences T...
Read ArticleA number of ASX shares in the S&P/ASX 200 Health Care Index (ASX: XHJ) outperformed the broad...
Read ArticleRecce Pharmaceuticals jumps on positive safety data during trial dosing participants with anti-infec...
Read ArticleShareCafeEvening Report: 21 June, 2022 by Melissa Darmawan Australian shares snapped a seven-day l...
Read ArticleRecce Pharmaceuticals (RCE) reports positive safety data in ten male subjects who received 4000mg o...
Read ArticleShareCafeLunch Report: 21 June, 2022 by Melissa Darmawan The Australian sharemarket is set to snap...
Read ArticleThe Recce Pharmaceuticals Ltd (ASX: RCE) share price is rebounding after hitting a near multi-yea...
Read Article21 Jun 2022 - A snapshot of the stocks on the move, featuring ResApp (ASX:RAP), Radiopharm Theranost...
Read ArticleResApp’s independent study of cough app falls short Recce Pharma completes Cohort 6 dosage in Phase...
Read ArticleShareCafeQueuing at the ATM: ASX small caps discover a handy source of funding ASX-listed small cap...
Read ArticleRecce Pharmaceuticals (RCE) sees its clinical trial receive a good safety profile among ten healthy...
Read ArticleThe healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak mark...
Read ArticleRecce Pharmaceuticals (RCE) is set to administer its “high dose” cohort following its successful ph...
Read ArticleChimeric wants to accelerate its clinical trial readiness via a deal with WuXi Recce advances to hi...
Read ArticleAustralia-based drug developer Recce Pharmaceuticals (RCE) granted a patent in Hong Kong for two of...
Read ArticleResApp gets takeover offer from Pfizer Recce gets Hong Kong patent RhinoMed comes out of trading ha...
Read ArticleRecce Pharmaceuticals (RCE) reports positive safety results from the fourth patient cohort in a fir...
Read ArticleHighlights Recce Pharmaceuticals’ R327 exhibits a safe and tolerable profile. The safety profil...
Read ArticleThe Tempest, a tale of love, revenge and family set at sea, is thought to be the last play that Will...
Read ArticleThrough their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to over...
Read ArticleASX-listed Recce Pharmaceuticals (RCE) has developed a synthetic anti-infective designed to not onl...
Read ArticleRecce Pharmaceuticals’ (RCE) new class of synthetic anti-infectives drug, the RECCE 327 (R327) has...
Read ArticleHighlights The ASX 200 was trading 0.31% up at 7,113.8 in the first 15 minutes of trading. Bren...
Read ArticleThe ASX 200 Health Index (XHJ) is trading lower by 1.40% at the time of writing, compared to the bro...
Read ArticleRecce Pharmaceuticals (RCE) doses the final three patients under cohort three of the Phase I intrav...
Read ArticleAt the time of writing, the ASX 200 Health Index (XHJ) is down by 1.90%, while the benchmark ASX 200...
Read Article“Completing this Cohort with the maximum number of subjects, sees R327 (500mg, I.V.) further a compe...
Read ArticleRecce Pharmaceuticals’ (RCE) phase-one intravenous clinical of R327 indicates a good safety and tol...
Read ArticleNeuroScientific Biopharmaceuticals (ASX:NSB) share price jumped ~13% today to 35 cents after an upda...
Read ArticleAccording to PEW Charitable Trusts global antibiotic pipeline review, R327 is the only clinical-stag...
Read ArticleRecce Pharmaceuticals (RCE) ended the December quarter with a cash balance of $15.83 million post r...
Read ArticleThe ASX 200 posted a small 0.11 fall on Tuesday, outperformed by the small end of town as the microc...
Read ArticleRecce Pharmaceuticals (RCE) has released positive safety data from its second cohort of subjects fo...
Read ArticleKey Points The Recce share price is up 3.85% to $1.35 An independent safety committee has cleared...
Read ArticleAccording to PEW Charitable Trusts global antibiotic pipeline review, RECCE 327 is the only clinical...
Read ArticleThe ASX has recovered following yesterday’s strong blow, closing up 1.29% with all 11 sectors finish...
Read ArticleRecce Pharmaceuticals (RCE) announces positive data from its phase one intravenous clinical trial f...
Read ArticleAccording to PEW Charitable Trust, R327 is the only clinical-stage new class of antibiotic in the wo...
Read ArticleSynthetic anti-infectives company Recce Pharmaceuticals (ASX:RCE) has announced it has recru...
Read ArticleR327 is administered as a single dose via a 1-hour IV infusion at a uniform rate, with all 80 subjec...
Read ArticleSynthetic anti-infective company Recce Pharmaceuticals (ASX:RCE) has provided an update on i...
Read ArticleRecce Pharmaceuticals’ share price has been boosted this morning on positive news about one of its d...
Read Article“This initial update builds upon strong pre-clinical data demonstrating fast and efficient killing a...
Read ArticleThe ASX 200 Health Index (XHJ) is down by 0.80% at the time of writing, compared to the broader inde...
Read ArticleRecce Pharmaceuticals (RCE) provides an update in the clinical trial of RECCE 327 (R327) for the tr...
Read ArticleThe Recce Pharmaceuticals Ltd (ASX: RCE) share price is soaring today. This comes after the pharmac...
Read ArticleIn October, the Chinese government released its intellectual proprietary (IP) patents strategy paper...
Read ArticleIn March this year, Recce listed on the Frankfurt Stock Exchange and is working with German asset ma...
Read ArticleReceiving human ethics approval is a momentous achievement for Recce and the clinicians seeking effe...
Read ArticleRecce Pharmaceuticals (RCE) has received Human Research Ethics Committee (HREC) approval to begin i...
Read ArticleThe ASX 200 Health Index (XHJ) is up by 0.80% at the time of writing, compared to the broader index...
Read ArticleThe misuse and overuse of antibiotics have led to the rapid growth of superbugs – a type of bacteri...
Read ArticleThe ASX retreated again as angst over inflation and the withdrawal of stimulus continued to weigh on...
Read ArticleThe Recce Pharmaceuticals Ltd (ASX: RCE) share price was halted today after the company made a key...
Read ArticleThe ASX had a positive end to the week with the ASX 200 gaining 0.87% today taking its weekly gain t...
Read ArticleSuperbugs that are resistant to antibiotics are causing an urgent global health crisis, but Recce Ph...
Read ArticleSummary Northern Star (ASX:NST) reports strong June quarter, shares move up Santos (ASX:STO) ju...
Read ArticleThe Recce Pharmaceuticals Ltd (ASX: RCE) share price ended the day higher after the company secured...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 7...
Read ArticleThe Aussie share market has fallen for two consecutive days, down by 0.46% today. Seven sectors were...
Read ArticleThe Recce Pharmaceuticals Ltd (ASX: RCE) share price is on the move today. It comes after the pharm...
Read ArticleRECCE® 327 (R327) has been shown to reduce deadly flesh-eating bacterial count below limit of quanti...
Read ArticleThe Australian share market has followed Wall Street’s lead, closing 0.85% lower in today’s trading....
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleThe Recce Pharmaceuticals Ltd (ASX: RCE) share price is falling after the company released an updat...
Read ArticleThe Recce Pharmaceuticals Ltd (ASX: RCE) share price has been a strong performer on Thursday. In af...
Read ArticleRecce Pharmaceuticals (ASX:RCE), a company developing new classes of synthetic anti-infectiv...
Read ArticleFollowing encouraging test results from stage1A and stage1B, RECCE® R327 received a qualified recomm...
Read ArticleThe market is trading near day’s high at the close, after the Reserve Bank of Australia’s (RBA) main...
Read ArticleSummary Digital health player ResApp Health has entered into a non-exclusive distribution agreem...
Read ArticleThe Australian share market continued to trade in positive on Tuesday afternoon, owing to favourable...
Read ArticleASX biotechs Recce Pharmaceuticals (ASX:RCE) and Botanix Pharmaceuticals (ASX:BOT) have this morning...
Read ArticleThe Recce Pharmaceuticals Ltd (ASX: RCE) share price has been a positive performer on Tuesday. In m...
Read ArticleRecce Pharmaceuticals (ASX:RCE) has announced that its RECCE 327 has demonstrated bactericid...
Read ArticleMixed start to the month on Wall Street Wall Street was mixed, with the Dow Jones and S&P500 ind...
Read ArticleThe Recce Pharmaceuticals Ltd (ASX: RCE) share price is slipping today after the company released i...
Read Article15 Apr 2021 - Recce Pharmaceticals’ (ASX:RCE) lead compound RECCE® 327 has been registered in the Au...
Read ArticleRecce Pharmaceuticals Ltd (ASX: RCE) shares are on the move in mid-afternoon trade. This comes afte...
Read ArticleThe first person formally treated with Recce Pharmaceutical’s (ASX:RCE) next-generation antibiotic c...
Read ArticleRecce Pharmaceuticals (ASX:RCE) has announced that a SAS Category A notification has been ma...
Read ArticleThe Recce Pharmaceuticals Ltd (ASX: RCE) share price rose 7% this morning after the company shared...
Read ArticleApr 2021 - Superbug and viral pathogen treatment developer Recce Pharmacetical (ASX:RCE)’s unapprove...
Read ArticleIn late morning trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record another decent g...
Read ArticleRecce Pharmaceuticals Ltd [ASX:RCE] is a prime example. With the stock trading 0.5% lower at time of...
Read ArticleThe Recce Pharmaceuticals Ltd (ASX: RCE) share price has spent today in the red despite the company...
Read ArticleSource:Guschenkova, Shutterstock Summary Recce Pharmaceutical disclosed that data from an anima...
Read ArticleThe Recce Pharmaceuticals Ltd (ASX: RCE) share price is pushing higher on Monday morning. At the ti...
Read ArticleSource: Shutterstock Summary ASX-listed world-leader in synthetic-polymer antibiotics Recce Pha...
Read ArticleIn late morning trade the S&P/ASX 200 Index (ASX: XJO) is on course to end the week with a decl...
Read ArticleThe Recce Pharmaceuticals Ltd (ASX: RCE) share price has been on fire on Friday morning. At the tim...
Read ArticleSummary Recce Pharmaceuticals announces positive animal data for its products RECCE® 327 and REC...
Read ArticleIn late morning trade the S&P/ASX 200 Index (ASX: XJO) is on course to bounce back from yesterd...
Read ArticleThe Recce Pharmaceuticals Ltd (ASX: RCE) share price is pushing higher on Wednesday after the relea...
Read ArticleSummary The near-festive season and recent relaxation in restrictions are having a positive effe...
Read Article26 Nov 2020 - Recce Pharmaceuticals Ltd (ASX:RCE) has been awarded over $17 million of Synthetic Ant...
Read ArticleThe Recce Pharmaceuticals Ltd (ASX: RCE) share price is shooting up today, after the company announ...
Read ArticleThe company is pioneering the development and commercialisation of new classes of synthetic anti-inf...
Read ArticleThe Recce Pharmaceuticals Ltd (ASX: RCE) share price has been soaring up today. Recce shares jumped...
Read ArticlePresenting companies were Cynata Therapeutics Ltd, Recce Pharmaceuticals Ltd and Pharmaxis Ltd (ASX:...
Read ArticleShareholders in Recce Pharmaceuticals Ltd (ASX: RCE) have been hitting the sell button today follow...
Read Article2020 has been a busy year for Recce Pharmaceuticals Ltd [ASX:RCE]. The biotech small-cap has been ti...
Read ArticleThe Recce Pharmaceuticals Ltd (ASX: RCE) share price is rocketing higher today following an update...
Read ArticleBy Peter Switzer, Switzer Report Lots of smaller companies I like One thing I’ve personally learnt t...
Read ArticleThe market may be dropping lower on Wednesday, but that hasn’t stopped the Recce Pharmaceuticals Lt...
Read ArticleIn early afternoon trade the S&P/ASX 200 Index (ASX: XJO) is on course to record a sizeable dec...
Read Article30 Sep 2020 - Recce Pharmaceuticals (ASX:RCE) has entered into an agreement with the Murdoch Childre...
Read ArticleThe Recce Pharmaceuticals Ltd (ASX: RCE) share price has come under pressure on Wednesday after ret...
Read ArticleIn late morning trade the S&P/ASX 200 Index (ASX: XJO) is on course to record a very strong gai...
Read ArticleWhile everyone has been busy looking at buy now, pay later (BNPL) shares, there are plenty of other...
Read ArticleShaw and Partners is pleased to be appointed as Lead Manager to an equity capital raising by Recce P...
Read ArticleGlobal investment giant Fidelity is poised to storm up the register of small cap listed drug develop...
Read ArticleActive investing will earn greater returns in a volatile market. That’s not just my opinion, but a...
Read ArticleThe Sydney-based biotechnology company recently announced a phase 1 trial aimed at new classes of sy...
Read ArticleToday has been very strong for a range of ASX sectors after yesterday’s market fall. We’ve seen the...
Read ArticleThe Australian share market was on form on Tuesday and stormed notably higher again. While a good n...
Read ArticleI’m a big believer in investing in quality ASX growth shares. If you had picked up Afterpay Ltd (AS...
Read ArticleRight now investors have a range of areas to choose great ASX shares for growth. On one hand we see...
Read ArticleMoney Talks is Stockhead’s regular drill down into the sectors and companies that investors have the...
Read ArticleThe Recce Pharmaceuticals Ltd (ASX: RCE) share price traded nearly 15% higher this morning after th...
Read ArticleA 10-bagger share is one that will return 10 times the initial investment. Over the past decade, th...
Read ArticleLast week, Recce Pharmaceuticals Ltd [ASX:RCE] had a major win. This tiny biocap stock divulged that...
Read ArticleA quick wrap of the ASX’s key winners and losers on Thursday, July 16. Data is taken after the marke...
Read ArticleOne week since announcing two of its compounds will be used in an upcoming antiviral SARS-CoV-2 scre...
Read ArticleOne of the best performers on the Australian share market on Thursday has been the Recce Pharmaceut...
Read ArticleIn late morning trade the S&P/ASX 200 Index (ASX: XJO) has given back its early gains and is dr...
Read ArticleI think that if you are going to make serious money on the share market, then you have to find 1 or...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleThe Australian medical sector has been one of the great drivers of innovation in global health for...
Read ArticleThe S&P/ASX 200 (INDEXASX: XJO) is expected to take a backwards step at the open this morning ac...
Read ArticleA quick wrap of the ASX’s key winners and losers on Thursday, July 9. Data is taken after the market...
Read ArticleThat’s where biotech companies like Recce Pharmaceuticals Ltd [ASX:RCE] come in. A small-cap that is...
Read ArticleRecce Pharmaceuticals (ASX: RCE) emerged from a trading halt to announced that two of its drug candi...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleSydney-based anti-infective company Recce Pharmaceuticals (ASX:RCE) has announced an Antivir...
Read ArticleThe Recce Pharmaceuticals Ltd (ASX: RCE) share price is on watch today after the company announced...
Read ArticleRecce Pharmaceuticals (RCE) Executive Director Michele Dilizia joins Peter Switzer.
Read ArticleBackpackers in Bondi were pilloried for spreading COVID-19, but everyone knows gonorrhoea is a great...
Read ArticleCOVID-19 may seem the only bug worth seeking to squash right now but there are at least two other ba...
Read ArticleA study into a new class of synthetic antibiotics developed by Recce Pharmaceuticals (ASX: RCE) has...
Read ArticleWhile we need all the bacteria fighters we can get right now, they are not immune to the coronovirus...
Read ArticleSydney-based Recce Pharmaceuticals (ASX:RCE), a company developing a new class of broad-spec...
Read ArticleRecce Pharmaceuticals (RCE) has announced positive data from its RECCE 327 antibiotic study on rats...
Read ArticleSince mid-October Zoono (ASX:ZNO) has climbed from 8.2c to $1.20 this morning — a 1,382 per cent spi...
Read ArticleWith triple the number of sepsis cases in Australia, small cap biotech company Cynata Therapeutics (...
Read ArticleAlso presenting at the CEO Sessions will be Great Boulder Resources, Recce Pharmaceuticals and Antis...
Read ArticleFive companies will present at Proactive’s CEO Sessions in Sydney on February 3 and Melbourne on Feb...
Read ArticleEvery week Stockhead publishes a weekly column of directors trades of $100,000 or more among ASX sma...
Read ArticleStockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picki...
Read ArticleIndustrial Sector or the secondary sector of the economy processes raw materials / inputs provided b...
Read ArticleIn the Australian health care system, three levels of government are responsible for providing unive...
Read ArticleFor a certain generation of investors the word ‘laser’ is indelibly tied to a Dr Evil reference. Ove...
Read ArticleE-sports, technology, biotech and primary producer stocks are all experiencing growing interest from...
Read ArticleOn Stockhead today: five water treatment stocks surge 260 per cent in a year, the ASX’s most intrigu...
Read ArticleSynthetic antibiotics developer Recce Pharmaceuticals has tasked Shaw and Partners with raising fres...
Read ArticleShaw and Partners has been appointed as Lead Manager to an equity capital raising by Recce Pharmaceu...
Read ArticlePublicly traded companies lay great emphasis on their respective share price, which mirrors their ov...
Read ArticleThe company is pioneering the development of a new class of synthetic antibiotics with broad-spectru...
Read ArticleThis week only six directors traded $100,000 or more. So we’ve also recapped some big directors’ tra...
Read ArticlePot stock Botanix (ASX:BOT) says one of its cannabis formulations kills superbugs — in animals and i...
Read Article
Open an account with an online broker of your choice. If you do not have an existing broker, consider Mawson Graham's A$9.50 flat fee platform.
Sign up now »Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.
